Alzheimer Caregiver Coping: Mental and Physical Health

阿尔茨海默病护理人员应对:心理和身体健康

基本信息

  • 批准号:
    7265643
  • 负责人:
  • 金额:
    $ 78.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-09-30 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This Alzheimer Caregiver Study has been exploring the physiological and psychological mechanisms that may be associated with increased health risk in groups of elderly spousal caregivers (CG). Results indicate that CG experience increased sympathoadrenalmedullary (SAM) arousal, which may be related to sleep disturbance, and associated with physiological changes previously linked to risk of cardiovascular (CV) disease, such as increase in circulating catecholamines, rise in the procoagulant factor D dimer, and the proinflammatory marker IL-6. Older CG show greatest changes. In the renewal we wish to develop a more complete mechanistic understanding of the stress to CV risk translation. The general hypotheses are that specific elements of the caregiving situation, such as problem behaviors of the care recipient and lack of respite induce affective arousal and sleep problems which favor a state of increased SAM arousal. Chronic SAM excitation favors the release of inflammatory markers such as IL-6, and a shift toward procoagulation. These physiological changes, if chronic, may lead to CV vulnerability, including hypertension and vascular endothelial injury. The buffering effects of coping that emphasize mastery will also be explored. A novel focus of this renewal application is our proposal to link the major markers of psychobiological stress related to caregiving (i.e., affective arousal, sleep disturbance, and biomarkers such as catecholamines, hemostatis variables, inflammatory markers) to indicators of CV injury including degree of endothelial injury, early signs of larger vessel pathology and baroreflex desensitization. The study design involves repeated observation of 120 spousal caregivers of Alzheimer patients and a comparison group of 60 non-caregivers. Using our unique strategy of "taking the laboratory to the home", participants will be assessed annually (with added assessments following placement or death of care recipient) with respect to their caregiving situation, psychological status, and several biological indicators (e.g. SAM arousal, sleep disturbance, pro-inflammatory and hemostasis molecules, baroreflex, measures of endothelial function, and large vessel disease). This study will provide a basis for a mechanistic understanding of the path from CG stress to CV morbidity in elderly CG, and opens the possibility of targeted interventions to reduce this risk.
描述(由申请人提供):这项阿尔茨海默氏症照顾者研究一直在探索可能与老年配偶照顾者(CG)群体健康风险增加相关的生理和心理机制。结果表明,CG的经验增加交感肾上腺髓质(SAM)唤醒,这可能与睡眠障碍,并与以前与心血管(CV)疾病的风险,如增加循环中的儿茶酚胺,促凝血因子D二聚体和促炎标志物IL-6的增加相关的生理变化。老CG显示最大的变化。在更新中,我们希望对压力到CV风险的转换有一个更完整的机械理解。一般的假设是,特定的元素,如问题行为的照顾接受者和缺乏喘息诱导情感唤醒和睡眠问题,有利于增加SAM唤醒的状态。慢性SAM兴奋有利于炎症标志物如IL-6的释放,并向促凝转变。这些生理变化,如果是慢性的,可能导致CV脆弱性,包括高血压和血管内皮损伤。强调掌握的应对的缓冲效应也将被探讨。这项更新申请的一个新焦点是我们建议将与抑郁相关的心理生物学压力的主要标志物(即,情感唤醒、睡眠障碍和生物标志物如儿茶酚胺、止血变量、炎症标志物)与CV损伤的指标(包括内皮损伤程度、较大血管病理学的早期体征和压力反射脱敏)相比较。研究设计包括重复观察120名阿尔茨海默病患者的配偶照顾者和60名非照顾者的对照组。使用我们独特的“将实验室带到家中”的策略,将每年对参与者进行评估(在护理接受者安置或死亡后进行额外评估),评估内容包括他们的生存状况、心理状态和几种生物指标(例如SAM觉醒、睡眠障碍、促炎和止血分子、压力反射、内皮功能测量和大血管疾病)。这项研究将提供一个机制的理解的路径CG压力CV发病率在老年CG的基础上,并打开了有针对性的干预措施,以减少这种风险的可能性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IGOR GRANT其他文献

IGOR GRANT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IGOR GRANT', 18)}}的其他基金

Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living with HIV
阻塞性睡眠呼吸暂停的内型及其对艾滋病毒感染者表型的影响
  • 批准号:
    10155554
  • 财政年份:
    2018
  • 资助金额:
    $ 78.59万
  • 项目类别:
Heroin abstinence induced HPA & SAM dysregulation disrupts HIV virologic control
海洛因戒断诱发 HPA
  • 批准号:
    8616999
  • 财政年份:
    2014
  • 资助金额:
    $ 78.59万
  • 项目类别:
Heroin abstinence induced HPA & SAM dysregulation disrupts HIV virologic control
海洛因戒断诱发 HPA
  • 批准号:
    8871706
  • 财政年份:
    2014
  • 资助金额:
    $ 78.59万
  • 项目类别:
California NeuroAIDS Tissue Network
加州神经艾滋病组织网络
  • 批准号:
    8540465
  • 财政年份:
    2013
  • 资助金额:
    $ 78.59万
  • 项目类别:
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH (CHARTER) EXTENSION
CNS HIV 抗逆转录病毒治疗效果研究(章程)扩展
  • 批准号:
    8737536
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH (CHARTER) EXTENSION
CNS HIV 抗逆转录病毒治疗效果研究(章程)扩展
  • 批准号:
    8910507
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:
CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) as a Resource
CNS HIV 抗逆转录病毒治疗效果研究 (CHARTER) 作为资源
  • 批准号:
    8163758
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:
CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) as a Resource
CNS HIV 抗逆转录病毒治疗效果研究 (CHARTER) 作为资源
  • 批准号:
    8540327
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:
International Core
国际核心
  • 批准号:
    8054310
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:
Coordinating Core
协调核心
  • 批准号:
    8054303
  • 财政年份:
    2010
  • 资助金额:
    $ 78.59万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 78.59万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 78.59万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 78.59万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 78.59万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 78.59万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 78.59万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 78.59万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 78.59万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 78.59万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 78.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了